The European Commission Has Authorized the Marketing of the Alzheimer’s Drug Leqembi in the European Union. The New Drug Already Received a Positive Assessment from the European Medicines Agency (EMA) in November for a Specific Group of Patients.
Only a relatively small group of patients can use the drug. Conditions include that the disease is not yet in an advanced stage and that the patient is generally healthy. Lecanemab, also Known Under The Brand Name Leqembi, Slows Down The Development of the Disease.
In Addition, The Recommendation Only applies to patients with only one or no copies of a specific that plays an important role in Alzheimer’s disease. This groups The Apoe4 Gene. People with Two Copies Of That Gene Have A Greater Chance of Side Effects, Such as Swelling and Bleding in the Brain.
The First Application to Market This Drug Within The Eu was Rejected by the Ema Due to An Excessive Risk of Side Effects.
Manufacturers Eisai and biogen then submitted a new application, which was approved by the ema. The European Commission Authorized the Marketing of the Drug In The Eu This Week.
Manufacturer Begins Assessment Process for Inclusion in Basic Package
“Leqembi Repressents An Important Step Forward in the Treatment of Neurodegenerative Disorders, Starting with Alzheimer’s Disease,” Says Jort Vijverberg, neurologist at the Alzheimer Center of Amsterdam UMC.
“AltheHeT is not a cure, the ability to slow cognitive decline gives patients and their families more precious time together and more autonomy. This is an invaluable.”
It is not Yet Known When Dutch Patients Will Be Able To Receive the Drug. The Dutch Branch of Pharmaceutical Company Eisai Submitted the Reimbursement File to the Zorgstituut Nederland on Wednesday. This has started the assessment process for the inclusion of leqembi in the basic package.